Key PointsSubstantial revenue from its flagship drug Casgevy should be right around the corner.
Publicznie pokazujemy glowna mysl. Utworz darmowe konto, aby czytac caly artykul, zapisac go, omowic i polaczyc z kontekstem rynkowym oraz OSINT.
Veytics Intelligence
Citi Sees 60% Upside in CRISPR Therapeutics. Here's What Has to Go Right.
